Abstract 2930
Background
Early diagnosis of cancer is an important factor in increasing success in treatment. Nursing and nursing students who take care of the patient in clinical area practices can have a major impact on the disease by providing early diagnosis of the cancer. Limited study was explored awareness of nursing student about the warning signs of cancer.
Methods
A cross-sectional descriptive study was conducted from January-March 2019. The sample size was measured Raosoft online calculator programme. A total of 460 nursing students participated in this study. Data was was obtained from nursing student via self-report using the data collection form developed by researchers based on literature. The Chi-square test was performed to evaluate differences among groups.
Results
The mean age of the nursing students was 20.05 ± 2.04; most of the students were female (82.6%). The knowledge level of warning signs of cancer of the students who were female was significantly higher than male students; as following; the symptoms of change in bowel or bladder habits (p = 0.001); unusual bleeding or discharge (p = 0.01); thickening or lump in the breast or elsewhere (p = 0.004); indigestion or difficulty in swallowing (p = 0.002); obvious change in a wart or mole (p = 0.003); nagging cough or hoarseness (p = 0.04). The knowledge level of warning signs of cancer of the students who took ’Internal Medicine Nursing’ lesson was significantly higher than others; as following; the symptoms of change in bowel or bladder habits (p = 0.000); a sore that doesn’t heal (p = 0.002); unusual bleeding or discharge (p = 0.03); indigestion or difficulty in swallowing (p = 0.000); obvious change in a wart or mole (p = 0.000); nagging cough or hoarseness (p = 0.001).
Conclusions
It is thought that the majority of nursing students know warning signs of the cancer and are associated with the education given in ’Internal Medicine Nursing’. It is recommended that nursing students take part in early diagnosis and screening programs in cancer. Female nursing students more aware than male students. Because; cancer prevention campaigns have focused breast and cervical cancer which involves only females. Cancer prevention campaigns should be organized for lung, prostate and colorectal cancer which are more common in men.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract